Pfizer (XSWX:PFE) Other Current Liabilities: CHF17,968 Mil (As of Mar. 2026)


XSWX:PFE Pfizer Inc XSWX:PFE
59 GF Score
Price CHF19.98
GF Value CHF21.37
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Pfizer Other Current Liabilities?

Pfizer XSWX:PFE 59 Other Current Liabilities is CHF17,968 Mil as of Mar. 2026. GuruFocus rates XSWX:PFE with a GF Score™ of 59/100 and a GF Value™ of CHF21.37 (Fairly Valued). The stock has 5 warning signs investors should review.

Pfizer's other current liabilities for the quarter that ended in Mar. 2026 was CHF17,968 Mil.

Pfizer's quarterly other current liabilities declined from Sep. 2025 (CHF17,949 Mil) to Dec. 2025 (CHF17,737 Mil) but then increased from Dec. 2025 (CHF17,737 Mil) to Mar. 2026 (CHF17,968 Mil).

Pfizer's annual other current liabilities increased from Dec. 2023 (CHF20,165 Mil) to Dec. 2024 (CHF21,004 Mil) but then declined from Dec. 2024 (CHF21,004 Mil) to Dec. 2025 (CHF17,737 Mil).

Pfizer Other Current Liabilities Related Terms

Pfizer Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Pfizer's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Other Current Liabilities Chart

Pfizer Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26,036.67 24,207.63 20,164.54 21,004.31 17,737.40

Pfizer Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19,990.57 17,094.28 17,948.87 17,737.40 17,967.76
XSWX:PFE
59GF Score
Pfizer Inc XSWX:PFE
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of CHF17,968 Mil mean?
Pfizer (XSWX:PFE) has a Other Current Liabilities of CHF17,968 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Pfizer.
Is Pfizer's Other Current Liabilities too high?
Pfizer's current Other Current Liabilities is CHF17,968 Mil. Overall, Pfizer has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Other Current Liabilities compare to GILD and BMY?
Pfizer's Other Current Liabilities of CHF17,968 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Pfizer. Pfizer's current Other Current Liabilities is CHF17,968 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (XSWX:PFE) is currently considered Fairly Valued. The stock's GF Value™ is CHF21.37, compared to a current price of CHF19.98 — trading 6.5% below its estimated fair value. The current Other Current Liabilities is CHF17,968 Mil. Pfizer's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Pfizer (XSWX:PFE), the current Other Current Liabilities is CHF17,968 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (XSWX:PFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of CHF19.98 is trading 6.5% below its estimated GF Value™ of CHF21.37. GuruFocus considers Pfizer to be Fairly Valued.

Key valuation signals for XSWX:PFE:

  • Other Current Liabilities: CHF17,968 Mil
  • GF Value™: CHF21.37 vs. price of CHF19.98 (6.5% below fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the XSWX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
59GF Score

Get the complete analysis for XSWX:PFE

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF19.98
Price
CHF21.37
GF Value